mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders

Bibliography

• APA. Diagnostic and statistical manual of mental disorders. 4th edition. DSM-IV American Psychiatric Association; Washington DC: 1994
   Google Scholar
• Jeste SS. The neurology of autism spectrum disorders. Curr Opin Neurol 2011;24:132-9
   PubMed Web of Science ®Google Scholar
• Matson JL, Nebel-Schwalm MS. Comorbid psychopathology with autism spectrum disorder in children: an overview. Res Dev Disabil 2007;28:341-52
   PubMed Web of Science ®Google Scholar
• CDC. Prevalence of autism spectrum disorders — autism and developmental disabilities monitoring network, 14 Sites, United States, 2008. MMWR 2012;61:1-19
   Google Scholar
• Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003;2:255-67
   PubMed Web of Science ®Google Scholar
• Huttenlocher PR. Neural plasticity. Harvard University Press; Cambridge: 2002
   Google Scholar
• Yizhar O, Fenno LE, Prigge M, Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011;477:171-8
   PubMed Web of Science ®Google Scholar
• Benvenuto A, Moavero R, Alessandrelli R, Syndromic autism: causes and pathogenetic pathways. World J Pediatr 2009;5:169-76
   PubMed Web of Science ®Google Scholar
• Hampson DR, Adusei DC, Pacey LK. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. Biochem Pharmacol 2011;81:1078-86
   PubMed Web of Science ®Google Scholar
• Shinohe A, Hashimoto K, Nakamura K, Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1472-7
   PubMed Web of Science ®Google Scholar
• Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 2003;33:93-7
   PubMed Web of Science ®Google Scholar
• Dolen G, Bear MF. Fragile x syndrome and autism: from disease model to therapeutic targets. J Neurodev Disord 2009;1:133-40
   PubMed Web of Science ®Google Scholar
• Kelleher RJ III, Bear MF. The autistic neuron: troubled translation? Cell 2008;135:401-6
   PubMed Web of Science ®Google Scholar
• Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast 2011;2011:297153
   PubMedGoogle Scholar
• Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat Rec (Hoboken) 2011;294:1646-52
   PubMedGoogle Scholar
• Hussman JP. Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. J Autism Dev Disord 2001;31:247-8
   PubMed Web of Science ®Google Scholar
• Rolf LH, Haarmann FY, Grotemeyer KH, Kehrer H. Serotonin and amino acid content in platelets of autistic children. Acta Psychiatr Scand 1993;87:312-16
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Halt AR, Stary JM, Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2002;52:805-10
   PubMed Web of Science ®Google Scholar
• Nishikawa S, Goto S, Hamasaki T, Involvement of reelin and Cajal-Retzius cells in the developmental formation of vertical columnar structures in the cerebral cortex: evidence from the study of mouse presubicular cortex. Cereb Cortex 2002;12:1024-30
   PubMed Web of Science ®Google Scholar
• Casanova MF, Buxhoeveden DP, Switala AE, Roy E. Minicolumnar pathology in autism. Neurology 2002;58:428-32
   PubMed Web of Science ®Google Scholar
• Casanova MF, Buxhoeveden DP, Switala AE, Roy E. Neuronal density and architecture (Gray Level Index) in the brains of autistic patients. J Child Neurol 2002;17:515-21
   PubMed Web of Science ®Google Scholar
• Chao HT, Chen H, Samaco RC, Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010;468:263-9
   PubMed Web of Science ®Google Scholar
• Isaacson JS, Hille B. GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. Neuron 1997;18:143-52
   PubMed Web of Science ®Google Scholar
• Hampson DR, Gholizadeh S, Pacey LK. Pathways to drug development for autism spectrum disorders. Clin Pharmacol Ther 2012;91:189-200
   PubMed Web of Science ®Google Scholar
• Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010;CD004677
   Google Scholar
• Branford D, Bhaumik S, Naik B. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 1998;42:301-6
   PubMed Web of Science ®Google Scholar
• Gurkan CK, Hagerman RJ. Targeted treatments in autism and fragile x syndrome. Res Autism Spectr Disord 2012;6:1311-20
   PubMed Web of Science ®Google Scholar
• McBride SM, Choi CH, Wang Y, Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005;45:753-64
   PubMed Web of Science ®Google Scholar
• Silverman JL, Tolu SS, Barkan CL, Crawley JN. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 2010;35:976-89
   PubMed Web of Science ®Google Scholar
• Burket JA, Herndon AL, Winebarger EE, Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders. Brain Res Bull 2011;86:152-8
   PubMed Web of Science ®Google Scholar
• Silverman JL, Smith DG, Rizzo SJ, Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med 2012;4:131ra51
   PubMed Web of Science ®Google Scholar
• Choi CH, Schoenfeld BP, Bell AJ, Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res 2011;1380:106-19
   PubMed Web of Science ®Google Scholar
• Michalon A, Sidorov M, Ballard TM, Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012;74:49-56
   PubMed Web of Science ®Google Scholar
• Li W, Cui Y, Kushner SA, The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005;15:1961-7
   PubMed Web of Science ®Google Scholar
• Ehninger D, Han S, Shilyansky C, Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med 2008;14:843-8
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Hessl D, Coffey S, A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46:266-71
   PubMed Web of Science ®Google Scholar
• Jacquemont S, Curie A, des Portes V, Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011;3:64ra1
   PubMed Web of Science ®Google Scholar
• Chang S, Bray SM, Li Z, Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 2008;4:256-63
   PubMed Web of Science ®Google Scholar
• Pacey LK, Heximer SP, Hampson DR. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 2009;76:18-24
   PubMed Web of Science ®Google Scholar
• Zupan B, Toth M. Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring. J Pharmacol Exp Ther 2008;327:820-6
   PubMed Web of Science ®Google Scholar
• McDonnell MN, Orekhov Y, Ziemann U. Suppression of LTP-like plasticity in human motor cortex by the GABAB receptor agonist baclofen. Exp Brain Res 2007;180:181-6
   PubMed Web of Science ®Google Scholar
• Oberman L, Eldaief M, Fecteau S, Abnormal modulation of corticospinal excitability in adults with Asperger's syndrome. Eur J Neurosci 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Oberman L, Ifert-Miller F, Najib U, Transcranial magnetic stimulation provides means to assess cortical plasticity and excitability in humans with fragile x syndrome and autism spectrum disorder. Front Synaptic Neurosci 2010;2:26
   Google Scholar
• Sansone SM, Widaman KF, Hall SS, Psychometric study of the aberrant behavior checklist in fragile x syndrome and implications for targeted treatment. J Autism Dev Disord 2012;42:1377-92
   PubMed Web of Science ®Google Scholar